Forecast

Buy	20
Hold	6
Sell	0

News Go to news feed

Uniqure rises after William Blair 'outperform' and progress on AMT-130

Uniqure shares gained about 2.4% in premarket trading after William Blair initiated coverage with an “Outperform” rating. Analysts are broadly optimistic (11 buy, 1 hold), and agreement with the FDA on an accelerated approval pathway for AMT-130 has boosted investor sentiment. Uniqure also benefited from a solid cash position and an amended credit facility with Hercules Capital; the recent roughly 175% rally from the 52-week low is seen as company-specific. » More on de.investing.com
uniQure receives FDA confirmation for accelerated BLA pathway for AMT-130 and reports sales increase

uniQure said the FDA confirmed in writing after a Type B meeting that a BLA filing for Huntington’s therapy AMT-130 is appropriate under an accelerated pathway based on existing clinical data. The company beat revenue consensus in Q2 with $5.84m, but reported a higher net loss per share due to increased selling, general and administrative expenses. uniQure plans to file regulatory applications in the US and the UK in Q3 2026, strengthened its balance sheet with a $259m capital raise and extended its cash runway to 2030. The announcements pushed the stock about 6.3% higher in premarket trading. » More on de.investing.com
UniQure beats revenue estimate and secures $259 million financing through 2030

UniQure reported Q2 revenue of $5.80 million, exceeding the consensus expectation of $5.47 million, while net loss widened due to higher selling, general and administrative and non‑operating expenses. The revenue increase was driven by higher license income; rising personnel and contractor costs reflect preparations for potential product launches. Through a follow‑on placement, UniQure raised $259 million and says this secures liquidity through 2030; regulatory filings for AMT‑130 are planned for Q3 2026 and topline four‑year data are expected in September 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, uniQure has already paid €0.95 in dividends. The last payout was in October 2023.

Financials

In the last quarter, uniQure had revenue of €5.12m and net profit of -€71.02m

(EUR)	June 2026	YoY
Revenue	5.12m	14.64%
Gross profit	511.71k	38.20%
Net profit	-71.02m	121.94%
EBITDA	-41.74m	172.22%

Fundamentals

Metric	Value
Market capitalization	€2.41bn
Number of shares	62.45m
52-week high/low	€38.93 - €4.26
Dividends	No
Beta	0.94
P/E ratio	-11.02
PEG ratio	1.04
P/B ratio	9.10
P/S ratio	165.35

Company profile

uniQure N.V. ist ein Gentherapie-Unternehmen, das sich mit der Entwicklung von Behandlungen für Patienten beschäftigt, die an genetischen und anderen verheerenden Krankheiten leiden. Das führende Programm des Unternehmens ist Etranacogene dezaparvovec (AMT-061), das sich in der Phase-III-Zulassungsstudie HOPE-B zur Behandlung der Hämophilie B befindet. Das Unternehmen entwickelt außerdem AMT-130, eine Gentherapie, die sich in einer klinischen Studie der Phase I/II zur Behandlung der Huntington-Krankheit befindet, sowie AMT-060, das sich in einer klinischen Studie der Phase I/II zur Behandlung der Hämophilie B befindet; AMT-210, ein Produktkandidat zur Behandlung der Parkinson-Krankheit; AMT-260 zur Behandlung der Temporallappenepilepsie; AMT-240, ein präklinischer Produktkandidat zur Behandlung der autosomal dominanten Alzheimer-Krankheit; und AMT-161 zur Behandlung der amyotrophen Lateralsklerose. uniQure N.V. wurde 1998 gegründet und hat seinen Hauptsitz in Amsterdam, Niederlande.